You are here

Alteogen

AstraZeneca signs Alteogen deal worth up to $1.35B for subcutaneous cancer drugs despite Merck-Halozyme patent drama

Fierce Pharma

Mon, 03/17/25 - 10:11 pm

subcutaneous drug delivery

Daiichi Sankyo partners Alteogen on subcutaneous Enhertu

Pharmaphorum

Fri, 11/8/24 - 11:37 am